IRIS UniCatt

Danese, Silvio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.288
NA - Nord America 3.634
AS - Asia 2.626
SA - Sud America 465
Continente sconosciuto - Info sul continente non disponibili 128
AF - Africa 62
OC - Oceania 6
Totale 11.209
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.532
IT - Italia 1.633
SG - Singapore 1.214
DE - Germania 1.194
CN - Cina 638
SE - Svezia 390
BR - Brasile 364
UA - Ucraina 295
FR - Francia 221
VN - Vietnam 207
GB - Regno Unito 133
IE - Irlanda 113
JP - Giappone 91
IN - India 89
ID - Indonesia 78
FI - Finlandia 74
BD - Bangladesh 64
TR - Turchia 63
RU - Federazione Russa 61
CA - Canada 54
HK - Hong Kong 43
NL - Olanda 38
AR - Argentina 36
MX - Messico 25
IQ - Iraq 24
ZA - Sudafrica 24
PL - Polonia 23
ES - Italia 19
KR - Corea 19
PK - Pakistan 15
RO - Romania 14
CO - Colombia 13
EC - Ecuador 13
AT - Austria 12
BE - Belgio 11
IR - Iran 11
VE - Venezuela 11
JO - Giordania 10
SA - Arabia Saudita 9
UZ - Uzbekistan 9
PY - Paraguay 8
CH - Svizzera 7
PH - Filippine 7
PT - Portogallo 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
CZ - Repubblica Ceca 6
AL - Albania 5
AU - Australia 5
EG - Egitto 5
GR - Grecia 5
JM - Giamaica 5
LT - Lituania 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
EU - Europa 4
HR - Croazia 4
KE - Kenya 4
MA - Marocco 4
PE - Perù 4
TN - Tunisia 4
AZ - Azerbaigian 3
BZ - Belize 3
CI - Costa d'Avorio 3
ET - Etiopia 3
IL - Israele 3
KG - Kirghizistan 3
LB - Libano 3
ME - Montenegro 3
SN - Senegal 3
AM - Armenia 2
AO - Angola 2
BY - Bielorussia 2
CG - Congo 2
EE - Estonia 2
HN - Honduras 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MD - Moldavia 2
MY - Malesia 2
OM - Oman 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SV - El Salvador 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BM - Bermuda 1
BO - Bolivia 1
CM - Camerun 1
DK - Danimarca 1
GL - Groenlandia 1
GY - Guiana 1
HU - Ungheria 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
Totale 11.073
Salva come PNG Salva come JPEG
Città #
Singapore 697
Chandler 418
Ashburn 406
San Jose 314
Milan 177
Jacksonville 165
Rome 147
San Mateo 132
Dublin 111
Beijing 95
New York 86
Nanjing 80
Nürnberg 78
Tokyo 78
Wilmington 72
Lauterbourg 71
Los Angeles 69
Jakarta 67
Hefei 66
Ann Arbor 63
Ho Chi Minh City 58
Boston 57
Dearborn 57
Hanoi 54
Munich 51
Princeton 46
Izmir 43
Frankfurt am Main 41
Hong Kong 41
Dallas 38
The Dalles 35
Houston 34
Woodbridge 32
Nanchang 31
Redwood City 31
Moscow 30
Palermo 30
Turin 30
São Paulo 29
Bari 26
Seattle 25
Bremen 22
Cattolica 22
Detroit 22
Santa Clara 21
Buffalo 20
Hebei 20
Marseille 20
Mountain View 20
Bologna 19
Florence 19
Boardman 18
Guangzhou 18
Naples 18
Atlanta 17
Council Bluffs 17
Lawrence 17
Shenyang 17
Changsha 16
Brooklyn 15
Chicago 15
Fairfield 15
Kunming 15
Pune 15
Toronto 15
University Park 15
Da Nang 14
Phoenix 14
Genoa 13
Hangzhou 13
Kent 13
Zhengzhou 13
Catania 12
Jiaxing 12
Johannesburg 12
Tianjin 12
Baghdad 11
Belo Horizonte 11
Norwalk 11
Rio de Janeiro 11
Warsaw 11
Amman 10
Castignano 10
Denver 10
Manchester 10
Montreal 10
Nuremberg 10
Orem 10
Seoul 10
Treviso 10
Udine 10
Vienna 10
Andover 9
Augusta 9
Brasília 9
Brussels 9
Helsinki 9
Paris 9
San Francisco 9
Shanghai 9
Totale 5.024
Salva come PNG Salva come JPEG
Nome #
Ruolo dei fattori psicologici nelle malattie infiammatorie croniche intestinali 1.782
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 372
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. 251
-High prevalence of celiac disease in patients with lactose intolerance 231
Early atherosclerosis in patients with inflammatory bowel disease. 216
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 216
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease 211
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 210
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 193
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 192
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. 183
Federated learning in inflammatory bowel disease: The future of privacy-preserving Artificial Intelligence 180
Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD) 179
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease 176
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 171
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 170
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. 157
-Extraintestinal manifestations in inflammatory Bowel disease. 154
Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease 149
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 149
Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication 144
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 144
A novel pathogenic role for microvasculature in inflammatory bowel disease. 142
The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation 142
Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? 141
Biological therapies for inflammatory bowel disease: research drives clinics. 135
Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events 131
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease 130
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer 130
A) Platelets: new players in the mucosal scenario of inflammatory bowel disease. 129
Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine 129
Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients 128
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing 126
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial 125
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer. 121
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 120
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 120
-Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation 116
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 115
Gender, chronic infection and myocardial infarction 114
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 111
Severe liver injury associated with zafirlukast 109
Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery 107
PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. 106
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement 106
Elevated homocysteine levels in patients with Raynaud's syndrome 101
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 101
Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international study 100
Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment. 99
ag) Antibody to alpha4beta7 integrin for ulcerative colitis. 98
Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer 94
ag) CD40 antisense based strategy for inflammatory bowel disease: shutting down multiple cellular communication systems. 94
Balanced propofol sedation administered by nonanesthesiologists: The first Italian experience 94
Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases 93
Folate in gastrointestinal health and disease 91
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease 91
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease 91
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study 90
Inflammatory bowel diseases and psychological issues: A new approach for a systematic analysis of the academic debate 90
Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials 89
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. 89
Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease 85
A) CD40L-positive platelets induce CD40L expression de novo in endothelial cells: adding a loop to microvascular inflammation. 84
Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality 83
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis 80
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 79
Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study 78
Genetic and nutritional predictors of hyperhomocysteinemia in inflammatory bowel disease 75
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease 73
Thrombotic complications in inflammatory bowel disease: a multifactorial etiology 72
ag) Chemokines in inflammatory bowel disease. 68
High prevalence of Helicobacter priori type I virulent strains in patients with systemic sclerosis [6] (multiple letters) 68
-Antibody to alpha4beta7 integrin for ulcerative colitis 64
Assessment of prothrombotic risk in patients with Behçet's disease should include homocysteine plasma levels 54
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference 47
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY) 18
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study 7
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY) 6
Totale 11.209
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.350
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.350
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022641 0 66 19 49 32 18 17 127 27 38 113 135
2022/20231.309 146 164 101 202 95 156 66 117 154 26 42 40
2023/2024771 41 190 48 46 62 78 50 32 22 47 69 86
2024/20251.274 46 38 129 52 125 50 70 75 158 121 238 172
2025/20263.484 507 115 218 411 617 146 533 200 260 234 151 92
2026/2027450 154 296 0 0 0 0 0 0 0 0 0 0
Totale 11.209